Adherence influencing factors in patients taking oral anticancer agents: A systematic review

Cancer Epidemiology

Volumn 38, Issue 3, 2014, Pages 214-226

  Mathes, Tim ^a   Pieper, Dawid ^a   Antoine, Sunya Lee ^a   Eikermann, Michaela ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Medication adherence; Neoplasms; Oncology; Oral anticancer agents; Oral chemotherapy; Patient compliance; Risk

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; IMATINIB; TAMOXIFEN;

BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; DATA EXTRACTION; DATA SYNTHESIS; DEPRESSION; EMBASE; ETHNIC GROUP; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MORBIDITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SELF REPORT; SOCIAL SUPPORT; SOCIOECONOMICS; SYSTEMATIC REVIEW; TREATMENT DURATION; MEDICATION COMPLIANCE; META ANALYSIS; NEOPLASMS; ORAL DRUG ADMINISTRATION; PSYCHOLOGY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS;

EID: 84900495951     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.03.012     Document Type: Review

References (45)

1. Banna G.L., Collovà E., Gebbia V., Lipari H., Giuffrida P., Cavallaro S., et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010, 36(8):595-605.
2. Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006, 17(2):205-210.
3. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1):44-47.
4. Wood L. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 2012, 16(4):432-438.
5. Foulon V., Schoffski P., Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 2011, 66(2):85-96.
6. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94(9):652-661.
7. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachée P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
8. Xu S., Yang Y., Tao W., Song Y., Chen Y., Ren Y., et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat 2012, 136(2):495-502.
9. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011, 126(2):529-537.
10. World Health Organization Adherence to long-term therapies: evidence for action 2003.
11. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 2011, The Cochrane Collaboration.
12. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
13. Hayden J.A., Chou R., Hogg-Johnson S., Bombardier C. Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews. J Clin Epidemiol 2009, 62(8):781-796.
14. Lehane E., McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007, 44(8):1468-1477.
15. National Institute for Health and Clinical Excellence The guidelines manual 2009, http://www.nice.org.uk/media/5F2/44/The_guidelines_manual_2009_-_All_chapters.pdf.
16. Gorenoi V., Schoenermark M.P., Hagen A. Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes (Structured abstract) 2007, German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI), Cologne.
17. Atkins L., Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006, 42(14):2271-2276.
18. Bhattacharya D., Easthall C., Willoughby K.A., Small M., Watson S. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012, 18(3):333-342.
19. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007, 25(6):481-496.
20. Font R., Espinas J.A., Gil-Gil M., Barnadas A., Ojeda B., Tusquets I., et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012, 107(8):1249-1256.
21. Grunfeld E.A., Hunter M.S., Sikka P., Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005, 59(1):97-102.
22. Hershman D.L., Kushi L.H., Shao T., Buono D., Kershenbaum A., Tsai W.Y., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010, 28(27):4120-4128.
23. Huiart L., Bouhnik A.D., Rey D., Tarpin C., Cluze C., Bendiane M.K., et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?. Eur J Cancer 2012, 48(13):1939-1946.
24. Kiguchi T., Tauchi T., Ito Y., Miyazawa K., Kimura Y., Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 2009, 33(3):506-508.
25. Larizza M.A., Dooley M.J., Stewart K., Kong D.C.M. Factors influencing adherence to molecular therapies in haematology-oncology outpatients. J Pharm Pract Res 2006, 36(2):115-118.
26. Lebovits A.H., Strain J.J., Schleifer S.J., Tanaka J.S., Bhardwaj S., Messe M.R. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65(1):17-22.
27. Lee C.R., Nicholson P.W., Ledermann J.A., Rustin G.J.S. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 1996, 17(2):99-103.
28. Lee C.R., Nicholson P.W., Souhami R.L., Deshmukh A.A. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992, 10(6):1007-1013.
29. Lee C.R., Nicholson P.W., Souhami R.L., Slevin M.L., Hall M.R., Deshmukh A.A. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993, 67(3):630-634.
30. Marques P.A.C., Pierin A.M.G. Factors that affect cancer patient compliance to oral anti-neoplastic therapy. Acta Paulista de Enfermagem 2008, 21:323-329.
31. Partridge A.H., Wang P.S., Winer E.P., Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21(4):602-606.
32. Richardson J.L., Marks G., Johnson C.A., Graham J.W., Chan K.K., Selser J.N., et al. Path model of multidimensional compliance with cancer therapy. Health Psychol 1987, 6(3):183-207.
33. Levine A.M., Richardson J.L., Marks G., Chan K., Graham J., Selser J.N., et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987, 5(9):1469-1476.
34. Saratsiotou I., Kordoni M., Bakogiannis C., Livadarou E., Skarlos D., Kosmidis P.A., et al. Treatment adherence of cancer patients to orally administered chemotherapy: insights from a Greek study using a self-reported questionnaire. J Oncol Pharm Pract 2011, 17(4):304-311.
35. Sedjo R.L., Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011, 125(1):191-200.
36. Zeeneldin A.A., Gaber A.A., Taha F.M. Does fasting during Ramadan trigger non-adherence to oral hormonal therapy in breast cancer patients?. J Egypt Natl Canc Inst 2012, 24(3):133-137.
37. Decker V., Spoelstra S., Miezo E., Bremer R., You M., Given C., et al. A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs 2009, 32(6):E20-E29.
38. World Health Organization List of Member States by WHO region and mortality stratum 2003, http://www.who.int/choice/demography/mortality_strata/en/index.html.
39. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59(1):56-66.
40. Denhaerynck K., Steiger J., Bock A., Schafer-Keller P., Kofer S., Thannberger N., et al. Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients. Am J Transplant 2007, 7:108-116.
41. Verbrugghe M., Verhaeghe S., Lauwaert K., Beeckman D., Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 2014.
42. Akerblad A.C., Bengtsson F., Holgersson M., von Knorring L., Ekselius L. Identification of primary care patients at risk of nonadherence to antidepressant treatment. Patient Prefer Adherence 2008, 2:379-386.
43. Balfour L., Tasca G.A., Kowal J., Corace K., Cooper C.L., Angel J.B., et al. Development and validation of the HIV Medication Readiness Scale. Assessment 2007, 14(4):408-416.
44. Mathes T., Antoine S.L., Pieper D., Eikermann M. Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 2014.
45. Egger M., Zellweger-Zähner T., Schneider M., Junker C., Lengeler C., Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997, 350(9074):326-329.